STRATA Skin Sciences, Inc. (NASDAQ:SSKN) is a medical technology company specializing in the development and commercialization of products for the treatment of dermatological conditions. The company focuses on providing innovative solutions for skin diseases, leveraging its expertise in laser technology. STRATA competes with other companies in the healthcare sector, such as Sensus Healthcare, Soleno Therapeutics, SenesTech, and Xcel Brands.
In evaluating STRATA's financial performance, the Return on Invested Capital (ROIC) and Weighted Average Cost of Capital (WACC) are crucial metrics. STRATA's ROIC is -58.59%, while its WACC is 7.66%. This results in a ROIC to WACC ratio of -7.65, indicating that the company is not generating returns above its cost of capital. This suggests inefficiencies in capital utilization.
Comparatively, Sensus Healthcare (SRTS) has a ROIC of -4.47% and a WACC of 9.98%, leading to a ROIC to WACC ratio of -0.45. Despite being negative, Sensus Healthcare is closer to breaking even, suggesting better capital management than STRATA. This positions Sensus as a relatively more efficient player in the market.
Other peers, such as Soleno Therapeutics and SenesTech, also face challenges with negative ROIC to WACC ratios of -13.35 and -12.79, respectively. These figures highlight the broader industry struggle to generate returns above the cost of capital. However, STRATA's ratio of -7.65 is notably better than Soleno and SenesTech, indicating a slightly more favorable position.
Xcel Brands, with a ROIC of -44.68% and a WACC of 4.91%, has a ROIC to WACC ratio of -9.10. While still negative, it is better than STRATA's ratio. This comparison underscores the competitive landscape where all companies are striving to improve their capital efficiency amidst financial challenges.
